ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA)

ClinicalTrials.gov ID: NCT05002777

Public ClinicalTrials.gov record NCT05002777. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 16, 2026, 11:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Open-label, Phase IIb Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (LUMINA 2)

Study identification

NCT ID
NCT05002777
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Sanofi
Industry
Enrollment
22 participants

Conditions and interventions

Interventions

  • rilzabrutinib Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 6, 2021
Primary completion
May 22, 2024
Completion
Dec 30, 2029
Last update posted
May 20, 2025

2021 – 2029

United States locations

U.S. sites
11
U.S. states
4
U.S. cities
10
Facility City State ZIP Site status
The Oncology Institute of Hope & Innovation Site Number : 8400006 Cerritos California 90703
TOI Clinical Research LLC_ Cerritos_Investigational Site Number: 8400006 Cerritos California 90703
TOI Clinical Research LLC_Glendale_Investigational Site Number: 8400006 Glendale California 91204
TOI Clinical Research LLC_Long Beach_Investigational Site Number: 8400006 Long Beach California 90805
University of Southern California_Investigational Site Number: 8400009 Los Angeles California 90033
TOI Clinical Research LLC_Santa Ana_Investigational Site Number: 8400006 Santa Ana California 92705
The Lundquist Institute_Investigational Site Number: 8400005 Torrance California 90502
TOI Clinical Research LLC_ Whittier_Investigational Site Number: 8400006 Whittier California 90602
Georgetown University Hospital_Investigational Site Number: 8400003 Washington D.C. District of Columbia 20007
Oncology & Hematology Associates of West Broward_Investigational Site Number: 8400002 Tamarac Florida 33321
Massachusetts General Hospital_Investigational Site Number: 8400001 Boston Massachusetts 02114

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05002777, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 20, 2025 · Synced May 16, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05002777 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →